Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.

[1]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[2]  M. Leboyer,et al.  Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia , 2010, Psychiatry Research.

[3]  S. Leucht,et al.  Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories , 2010, Biological Psychiatry.

[4]  M. Berk,et al.  Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention , 2010, Schizophrenia Research.

[5]  H. Möller,et al.  The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity , 2010, European Archives of Psychiatry and Clinical Neuroscience.

[6]  H. Möller,et al.  Should the PANSS be rescaled? , 2010, Schizophrenia bulletin.

[7]  S. Kapur,et al.  The heterogeneity of antipsychotic response in the treatment of schizophrenia , 2010, Schizophrenia Research.

[8]  H. Möller,et al.  Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study , 2009, European Psychiatry.

[9]  A. Mackinnon,et al.  Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients , 2009, Schizophrenia Research.

[10]  H. Möller,et al.  Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. , 2009, Archives of general psychiatry.

[11]  H. Möller,et al.  Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. , 2008, The international journal of neuropsychopharmacology.

[12]  H. Möller,et al.  Structural brain alterations at different stages of schizophrenia: A voxel-based morphometric study , 2008, Schizophrenia Research.

[13]  D. Linszen,et al.  Improvement of Subjective Well-being and Enduring Symptomatic Remission, A 5-Year Follow-up of First Episode Schizophrenia , 2008, Pharmacopsychiatry.

[14]  J. Haro,et al.  Predictors of the course of illness in outpatients with schizophrenia: A prospective three year study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  J. Kane,et al.  Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia , 2008, Schizophrenia Research.

[16]  R. Baker,et al.  Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia , 2007, Schizophrenia bulletin.

[17]  J. Haro,et al.  Gender differences in response to antipsychotic treatment in outpatients with schizophrenia , 2007, Psychiatry Research.

[18]  H. Möller,et al.  Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. , 2007, The Journal of clinical psychiatry.

[19]  H. Lane,et al.  Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. , 2007, The Journal of clinical psychiatry.

[20]  J. Vázquez-Barquero,et al.  Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. , 2007, Journal of psychiatric research.

[21]  J. Kane,et al.  Early prediction of antipsychotic nonresponse among patients with schizophrenia. , 2007, The Journal of clinical psychiatry.

[22]  John M. Davis,et al.  Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs , 2007, Neuropsychopharmacology.

[23]  Yue-Cune Chang,et al.  Optimizing Early Prediction for Antipsychotic Response in Schizophrenia , 2006, Journal of clinical psychopharmacology.

[24]  R. Emsley,et al.  Remission in first-episode psychosis: predictor variables and symptom improvement patterns. , 2006, The Journal of clinical psychiatry.

[25]  Peter B. Jones,et al.  Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. , 2005, Archives of general psychiatry.

[26]  J. Lépine,et al.  Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study , 2005, International clinical psychopharmacology.

[27]  J. Kane,et al.  Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended , 2005, Biological Psychiatry.

[28]  S. Kapur,et al.  Evidence for onset of antipsychotic effects within the first 24 hours of treatment. , 2005, The American journal of psychiatry.

[29]  D. Weinberger,et al.  Remission in schizophrenia: proposed criteria and rationale for consensus. , 2005, The American journal of psychiatry.

[30]  H. Möller,et al.  German research network on schizophrenia , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[31]  J. Addington,et al.  Symptom Outcome 1 Year after Admission to an Early Psychosis Program , 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[32]  S. Kapur,et al.  Delayed onset hypothesis of antipsychotic action — a hypothesis tested and rejected , 2003, Schizophrenia Research.

[33]  S. Marder,et al.  Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. , 2002, The Journal of clinical psychiatry.

[34]  H. Rüdiger,et al.  Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs , 2001, Schizophrenia Research.

[35]  S. Siris.  Suicide and schizophrenia , 2001, Journal of psychopharmacology.

[36]  C. Cording.  [Conceptual aspects in development and implementation of basic psychiatric documentation]. , 1998, Psychiatrische Praxis.

[37]  M. Seeman.  The role of estrogen in schizophrenia. , 1996, Journal of psychiatry & neuroscience : JPN.

[38]  M. Bernardo,et al.  Positive versus negative symptoms in schizophrenia: Response to haloperidol , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  Lewis A. Opler,et al.  Reliability and validity of the positive and negative syndrome scale for schizophrenics , 1988, Psychiatry Research.

[40]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[41]  M. Myrtek,et al.  The law of initial value: A rare exception , 1986, Biological Psychology.

[42]  H. Möller,et al.  Vorhersage des Therapieerfolges unter neuroleptischer Akutbehandlung: Ergebnisse einer empirischen Untersuchung an 243 stationär behandelten schizophrenen Patienten , 1985 .

[43]  M. Alpert,et al.  The Neuroleptic Hypothesis: Study of the Covariation of Extrapyramidal and Therapeutic Drug Effects , 1978, British Journal of Psychiatry.

[44]  Thomas F. DeRosa,et al.  PSYCHIATRIC , 1970 .

[45]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[46]  S. Kapur,et al.  Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia , 2010, Neuropsychopharmacology.

[47]  A. Schene,et al.  Predictors of the early 5-year course of schizophrenia: a path analysis. , 2005, Schizophrenia bulletin.

[48]  W. Gaebel,et al.  Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. , 1998, Schizophrenia bulletin.

[49]  J. Lieberman,et al.  Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. , 1996, The Journal of clinical psychiatry.

[50]  R. Elston,et al.  Linkage analysis of pure depressive disease. , 1989, Journal of psychiatric research.

[51]  H. Möller,et al.  Prediction of long-term outcome in schizophrenia by prognostic scales. , 1986, Schizophrenia bulletin.

[52]  J. Strauss,et al.  Part II. Measuring Premorbid Adjustment: The Instruments and Their Development* , 1977 .